UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors

Drug metabolism and pharmacokinetics, 2024-04, Vol.55, p.100591, Article 100591

Bueters, Tjerk JH

2024

Volltextzugriff (PDF)

Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts

European journal of pharmaceutical sciences, 2017-11, Vol.109, p.S72-S77

2017

Volltextzugriff (PDF)

Selective effects of carbamate pesticides on rat neuronal nicotinic acetylcholine receptors and rat brain acetylcholinesterase

Toxicology and applied pharmacology, 2003-12, Vol.193 (2), p.139-146

2003

Volltextzugriff (PDF)

Block of Neuronal Nicotinic Acetylcholine Receptors by Organophosphate Insecticides

Toxicological sciences, 2004-12, Vol.82 (2), p.545-554

2004

Volltextzugriff (PDF)

Correct assessment of new compounds using in vivo screening models can reduce false positives

Drug discovery today, 2009, Vol.14 (1), p.89-94

2009

Volltextzugriff (PDF)

Cardiovascular effects of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning

Archives of toxicology, 2004, Vol.78 (1), p.34-39

2004

Volltextzugriff (PDF)

Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action

Neuroscience letters, 2003-05, Vol.343 (1), p.57-61

2003

Volltextzugriff (PDF)

Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree

European journal of pharmacology, 2003-11, Vol.481 (2), p.141-146

2003

Volltextzugriff (PDF)

Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats

Toxicology and applied pharmacology, 2003-10, Vol.192 (1), p.86-94

2003

Volltextzugriff (PDF)

Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication

Archives of toxicology, 2002-11, Vol.76 (11), p.650-656

2002

Volltextzugriff (PDF)

Correct assessment of new compounds using in vivo screenig models can educe false positives

Drug discovery today, 2009, Vol.14 (1-2), p.89-94

2009

Volltextzugriff (PDF)

Partial adenosine A1 receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice

European journal of pharmacology, 2003-06, Vol.471 (2), p.97-104

2003

Volltextzugriff (PDF)

Partial adenosine A(1) receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice

European journal of pharmacology, 2003-06, Vol.471 (2), p.97

2003

Volltextzugriff (PDF)

Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release

European journal of pharmacology, 2002-11, Vol.454 (2-3), p.177-182

2002

Volltextzugriff (PDF)

Cardiovascular effects of the adenosine A1 receptor agonist N 6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning

Archives of toxicology, 2004-01, Vol.78 (1), p.34-39

2004

Volltextzugriff (PDF)

Adenosine A 1 Receptor Agonist N 6 -Cyclopentyladenosine Affects the Inactivation of Acetylcholinesterase in Blood and Brain by Sarin

The Journal of pharmacology and experimental therapeutics, 2003-03, Vol.304 (3), p.1307-1313

2003

Volltextzugriff (PDF)

Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin

The Journal of pharmacology and experimental therapeutics, 2003-03, Vol.304 (3), p.1307

2003

Volltextzugriff (PDF)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Circulation (New York, N.Y.), 2023-07, Vol.148 (2), p.144-158

2023

Volltextzugriff (PDF)

Transforming Translation Through Quantitative Pharmacology for High‐Impact Decision Making in Drug Discovery and Development

Clinical pharmacology and therapeutics, 2020-06, Vol.107 (6), p.1285-1289

2020

Volltextzugriff (PDF)

Protective activity of adenosine receptor agonists in the treatment of organophosphate poisoning

Trends in pharmacological sciences (Regular ed.), 1999-11, Vol.20 (11), p.438-441

1999

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors

Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts

Selective effects of carbamate pesticides on rat neuronal nicotinic acetylcholine receptors and rat brain acetylcholinesterase

Block of Neuronal Nicotinic Acetylcholine Receptors by Organophosphate Insecticides

Correct assessment of new compounds using in vivo screening models can reduce false positives

Cardiovascular effects of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning

Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action

Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree

Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats

Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication

Correct assessment of new compounds using in vivo screenig models can educe false positives

Partial adenosine A1 receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice

Partial adenosine A(1) receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice

Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release

Cardiovascular effects of the adenosine A1 receptor agonist N 6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning

Adenosine A 1 Receptor Agonist N 6 -Cyclopentyladenosine Affects the Inactivation of Acetylcholinesterase in Blood and Brain by Sarin

Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Transforming Translation Through Quantitative Pharmacology for High‐Impact Decision Making in Drug Discovery and Development

Protective activity of adenosine receptor agonists in the treatment of organophosphate poisoning

Suchergebnisse filtern